INTERSECT ENT, INC. Lisa Earnhardt Named to FierceMedicalDevices'
'Top Women in Medical Devices' 2014
Menlo Park, Calif. - Oct. 24, 2014 - Intersect ENT, Inc. (NASDAQ: XENT) today announced that the company has been named the #1 Fastest Growing Private Company by the Silicon Valley Business Journal and the #2 Fastest Growing Private Company by the San Francisco Business Times. The lists rank private companies according to their three-year percent change in revenue from 2011 to 2013. Intersect ENT became a publicly held company in July 2014.
'This recognition is an incredible testament to the team that has made this accomplishment possible,' said Lisa Earnhardt, president and CEO of Intersect ENT. 'I'm proud of the dedication of our employees, together with our physician customers, to improve the lives of patients with ear, nose and throat conditions.'
In addition, Lisa Earnhardt was recently named as one of FierceMedicalDevices' 'Top Women in Medical Devices.' The inaugural list includes 13 female leaders in the medical technology representing major companies, startups, venture capital, industry advocates and academics who 'represent some of the major shifts and trends within the industry.'
Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two drug-eluting implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new drug-eluting implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
650.454.0504
nicole@nicoleosmer.com
|
distributed by
|
